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Summary: Fifty-six pregnant women (gestational age 6—40 weeks) were evaluated for their coagulation
activation (fibrin monomers and thrombin-antithrombin III complex) and for their fibrinolysis profile by
determining tissue plasminogen activator, plasminogen activator inhibitor, plasminogen, a2-antiplasmin- and
D-dimer. Fibrin monomers and thrombin-antithrombin III complexes were found to be significantly increasing
with gestational age. All the fibrinolytic parameters showed a steady growth with the progress of the pregnancy,
with the exception of tissue plasminogen activator which showed a significant decrease with gestational age,
but mainly within the reference ränge. These results suggest a Stimulation of the coagulation System and an
activation of fibrinolysis with ongoing pregnancy, although the increasing oc2-antiplasmin and plasminogen
levels and the decreasing tissue plasminogen activator concentrations do not conform to this trend.
Introduction
From the literature, it is known that coagulation
factors are increased during pregnancy, and this is
particularly manifest in the third trimester. This is
most striking in the case of the plasma fibrinogen
concentration (l —4), but it is also observed for factor
VII and factor VIII, into a moderate extent for factor
IX, faetor X and factor XII. Factor II and factor V
remain unchanged, whereas factor XI and XIII even
show a decrease (5 — 7). The geüeral impression is that
of a stäte of hypercoagulability, leading to the gen-
eration of thrombin. Once thrombin is formed, a
sefies of reactions would be initiated leading not only
to activation of the clotting factors II, V, VIII and
XIII äs a kind of positive feedback, but also of the
last part of the coagulation cascade (fig. 1). Interac-
tion with fibrinogen äs a Substrate results in the for-
mation of fibrin monomers and subsequently of in-
soluble fibrin.
Interaction with ahtithrombin III äs the regulator
protein for thrombin activity leads to the formation
of thrombin-antithrombin III complex. The forma-
tion of fibrin secondarily promotes the fibrinolysis
Anlithrombin III
Thrombin • Thrombin-antithrombin-III
Fibrinogen Fibrin monomer + FpA -l· FpB
Factor XHIa
"Cross-linked" fibrin, insoluble
Plasmin
D-dimer
Fig. l. Relevant part of the coagulation cascade
Fp = Fibrinopeptide
System which produces the fibrinolytic agent, plasmin.
Interaction of plasmin and fibrin produces the so
called D-dimers, D-fragment dimers originating from
cross-linked fibrin. There is much evidence that during
pregnancy fibrinolytic activity (measured by means of
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thc euglobulin clot lysis method and the fibrin plate
method) is diminished, especially in the last trimester
(5,8-12).
More recent studies show that the plasminogen acti-
vator inhibitor also steadily increases throughout
pregnancy (13, 14), whereas a special elevation is seen
in pre-eclampsia (15, 16). Recently several new tests
became available both for the investigation of coag-
ulation activation and for the assessment of the level
of fibrinolytic parameters. The aim of the present
study was to collect Information about the state of
coagulation and fibrinolysis in the course of preg-
nancy. For this purpose the coagulation parameters,
fibrin monomers and thrombin-antithrombin III, äs
well äs the fibrinolysis parameters, D-dimer, tissue
plasminogen activator, plasminogen activator inhibi-
tor, plasminogen and a2-antiplasrnin, were deter-
mined.
Materials and1 Methods
Ind iv idua i s
Fifty-six pregnant women attending the department of gynae-
cology and obstetrics for monitoring of their pregnancy were
included in the study. For the evaluation they were ranked
according to their gestational age. The known duration of the
gestation varied from 6—40 weeks and was based upon the last
menstrual date and ultra sound determinations. Only patients
whose last menstrual date and ultra sound determinations were
congruent, were included in the study. As a control group we
had at our disposal a group of subjectively healthy female
hospital staff äs well äs female laboratory workers.
Blood samples
Blood samples were drawn between 8.30 and 9.00 a. m. after
fasting overnight after a resting period of 20 min. Except for
tissue plasminogen activator activity, all coagulation and fibri-
nolysis parameters were determined in citrated plasma. This
was prepared by centrifugation of a mixture of nine volumes
freshly drawn blood with one volume trisodium citräte (0.11
mol/1) for 30 min (1600g) at 25 °C. The plasma was stored at
-70°C in plastic tubes and thawed with tap water for 5min
before serial analysis.
For the measurement of tissue plasminogen activator, l rnl
citrated blood was added to 0.5 ml acetate buffer (pH 3.9), the
mixture centrifuged immediately (30 min, 1800g) and the
plasma separated. The collected plasma was acidified with acetic
acid (200 ml glacial acetic acid + 800 ml H2O; final pH of the
plasma sample 4.0-4.1). This plasma was stored at -70 °C in
plastic tubes and thawed with tap water for 5 min before anal-
ysis.
Methods
The fibrin monomer test was carried out with the Kabi Vitrum
Diagnostica test kit Coa-set FM. For the thrombin-antithrom-
bin III determination the Elisa kit of the Behring/Hoechst
Corporation (Marburg, Germany) was employed. The Elisa D-
dimer determination was performed with the test kit from the
Boehringer Mannheim Corporation (Germany).
Plasminogen activator inhibitor äs well äs tissue plasminogen
activator were quantitated by measuring the enzymatic activity
of thc plasmin generated in presence of fibrinogen Fragments
towards the synthetic Substrate S-2251 (Kabi Vitrum Diagnos-
tica).
Plasminogen and a2-antiplasmin reagents were from Kabi Vi-
trum Diagnostica (Coatest plasminogen and Coatest a2^anti-
plasmin), both using the chromogenic substate S-2251.
Statistical analysis
Correlations were determined by linear regression analysis with
the method of the least squares.
For the Statistical comparison, Studenfs t-test was used.
Results
From 56 women with clinically normal pregnancies,
the coagulation and fibrinolysis parameters, fibrin
monomers, thrombin-antithrombin III, D-dimer,
plasminogen, a2-antiplasmin, tissue plasminogen ac-
tivator and plasminogen activator inhibitor were stüd-
ied for their correlation with gestational age. The
results are summarized in table l and figures 2—8.
Tab. 1. Correlation between gestational age and different co-
agulation and fibrinolysis parameters.
Linear correlation
between gestational
age and
Fibrin monomers
Thrombin-antithrom-
bin III
D-dimer
Plasminogen
a2-Antiplasmin
Tissue plasminogen
activator
Plasminogen activa-
tor inhibitor
r
0.51
0.60
0.58
0.38
0.27
-0.42
0.79
y = a
a
7.8
0.79
-5.26
121.1
99.3
2.08
-3.28
+ bx
b
0.16
0.27
34.1
0.87
0.32
-0.04
0.43
Signifi-
cance
P
0.002
< 0.0001
< 0.0001
0.003
0.044
0.003
< 0.0001
22
16
13
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10 20 30
Gestational· age [weeks]
Fig. 2. Correlation between fibrin monomers and gestational
age (r = 0.51, p = 0.002). ,'/
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Fig. 3. Correlation between thrombin-antithrombin III conv
plexcs and gestational age (r = 0.60, p < 0.0001).
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Fig. 6. Correlation between a2-anliplasmin and gestational age
(r = 0.27, p = 0.044).
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Fig. 4. Correlation between D-dimer and gestational age
(r = 0.58, p < 0.0001).
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Fig. 7. Correlation between tissue plasminogen activator and
gestational age (r = -0.42, p = 0.003).
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Fig. 5. Correlation between plasminogen and gestational age Fig. 8. Correlation between plasminogen activator inhibitor
(r = 0.38, p ss 0.003). and gestational age (r = 0.79, p < 0.0001).
AU = arbitrary units
All Parameters were statistically significant on the 5% mers a coefficient of correlation (r) of 0.51 (p = 0.002)
level of significancy. The coefficients of correlation was found, for thrombin-antithrombin III r = 0.60
indicated positive correlations for all but one (tissue (p < 0.0001), for D-dimer r = 0.58 (p < 0.0001), for
plasminogen activator) parameter. For fibrin mono- plasminogen r = 0.38 (p = 0.003), for a2-antiplasmin
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Tab. 2. Position of thc paramctcrs with regard to the refcrcnce
ranges (in brackcls)
Parameter x
Fibrin monomers 12.2
(8.4-1 3.2 nmol/1)
Thrombin-antithrom- 7.6
bin III
(1.0-4.1 /1)
D-dimer 852
(0-450
 §/1)
Tissue plasminogen 1.1
activator
(0.5-2.3 1 03 AU/1)
Plasminogen activa- 7.6
tor inhibitor
(0-4.6 103 AU/l)
Plasminogen . 143
(85-130%)
ot2-Antiplasmin 107
(80-120%)
SD Values
beneath
the lower
reference
ränge limit
3.2 0
4.6 0
597 0
1.0 20.4
5.5 0
23 0
12 0
Values
above
the upper
reference
ränge limit
71.1
78.6
76.8
7.1
64.3
71.4
14.3
r = 0.27 (p = 0.044), and for plasminogen activator
inhibitor r = 0.79 (p < 0.0001). The only negative
correlation with gestational age was found for tissue
plasminogen activator: r = —0.42 (p = 0.003). Table
2 shows the position of the parameters overall in
relation to the reference ranges. Only tissue plasmin-
ogen activator showed decreased äs well äs increased
values (20.4 versus 7.1%). For all other parameters a
considerable proportion of the data exceeded the up-
per limit of the respective reference ranges: for fibrin
monomers 71.1%, for thrombin-antithrombin III
78.6%, for D-dimer 76.8%, for plasminogen activator
inhibitor 64.3%, for plasminogen 71.4%, and for a2-
antiplasmin 14.3% of values exceeded the respective
upper reference limit.
Discussion
The evaluation and Interpretation of pfotein changes
during pregnancy is complicated by the fact that they
decrease with gestational age. This phenomenon is
well known for total serum protein and serum albu-
min and is due to the redistribution of body water
(i. e. rise of the plasma volume) with increasing ges-
tational age (17). Also clotting and fibrinolysis pa-
rameters might undergo the same dilution effect. It
therefore is the more astonishing that nevertheless 6/
7 clotting and fibrinolysis parameters increase signif-
icantly with gestational age. Until now the general
impression was that the changes in coagulation pa-
rameters corresponded to a state of hypercoagulabil-
ity. In this study we confirmed this Statement by
measuring fibrin monomers and thrombin-antithrom-
bin III, both of which increase with gestational age,
the levels being especially elevated in the last trimester
of the pregnancy. These findings are in concordance
with earlier reports (3,18) in which circulating soluble
fibrin monomer complexes were demonstrated from
the beginning of the second month of the pregnancy,
attaining maximal values five times the starting level
at the end of gestation.
Fibrinolytic activity has been reported to be dimin-
ished in the last trimester of pregnancy (5, 8—10,12)
when measured with the euglobulin clot lysis time and
the fibrin plate lysis method. Moreover, several anti-
plasmins showed a signifieant trend to an increase
during pregnancy, which might also imply a decrease
in fibrinolytic activity (2, 6). In this study we found
that the a2-antiplasmin activity and the plasminogen
levels increase with the gestational age. Plasminogen
activator inhibitor levels also increased significantly
and steadily with gestational age. These results are in
agreement with previous reports by Wiman et al. (13)
and Kruithofti al. (14). It should be pointed out that
the measured plasminogen activator inhibitor fraction
consists of plasminogen activator inhibitor-1 and plas-
minogen activator inhibitor-2. Plasminogen activator
inhibitor-1 is considered to be mainly an endothelium
component (19), whereas plasminogen activator in-
hibitor-2 originates from the placenta (20). Plasmin-
ogen, the natural occurring Substrate of plasmin, is
probably synthesized in the liver but also produced
or stored by the eosinophil granulae. It can act in
cooperation with a heparin binding basic protein äs
a local coagulation inhibitor (21). Possibly this is of
importance, because there are several reports both of
thrombotic manifestations in plasminogen deficiency
and in plasminogen abnormalities (22) and of con-
genital plasminogen deficiency in relation to venous
thrombosis (23). High plasminogen levels might be a
protective measure against the over-activation of clot-,,
ting. On the other hand it could be a reflection of
diminished plasmin generation. Indeed tissue plas-
minogen activator is the only one of the parameters
which is found to be diminishing with gestational age.
One would therefore expect a drop of the fibrinolytic
activity during pregnancy. This conclusion can how-
ever not be drawn, when considering the overall end-
effect of the fibrinolytic System during pregnancy: a
signifieant increase of the D-dimer concentration with
gestational age and 76.8% of the values above the
upper limit of the reference ränge,
 fThis is in agreement
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with earlier studies of Arooha-Pinango (4), Gilabert
(18) and Gordon (24), who reported indications of
elevated fibrinolytic activity in vivo by demonstrating
enhanced concentrations of fibrin(ogen) degradation
products in the peripheral blood during the last
trimester of pregnancy. Ballegeer et al. (25), however,
demonstrated increasing levels of D-dimers with ges-
tational age. These results indirectly suggest coagu^
lation activation. Apparently, however, there is a kind
of balance between coagulation activation and reac-
tive fibrinolysis during perpetuation of pregnancy,
although there is a tendency for tissue plasminogen
activator to decrease and for plasminogen activator
inhibitor and ot2-antiplasmin to increase with increas-
ing gestational age.
In summary, during the progress of pregnancy there
is an elevation of coagulation parameters (fibrin mon-
omers, thrombin-antithrombin III) and of the fibri-
nolysis parameters, plasminogen, a2-antiplasmin,
plasminogen activator inhibitor-1 and D-dimers,
whereas tissue plasminogen activator showed a ten-
dency to decrease. Especially the increasing levels of
plasminogen activator inhibitor-1 and a2-antiplasmin
äs well äs the decreasing tissue plasminogen activator
levels are however not sufficient to impair the actual
fibrinolytic activity, äs can be concluded from the
steadily increasing concentrations of the D-dimers. It
therefore remains questionable äs to whether the com-
bination of results allows the conclusion that the
fibrinolytic activity decreases, leading to a thrombotic
tendency during prengnancy, äs stated earlier (13).
The results reported here indicate a shift of coagula-
tion and fibrinolysis during normal pregnancy. The
findings can be valuable äs a basis for the proper
evaluation of the parameters studied in patients with
risk pregnancies like pre-eclampsia, suspected foetal
growth retardation, diabetes mellitus and thrombosis.
References
1. Oliver R. D., Patterson, B. B. & Puls, J. L. (1976) Thrombin
clottable determination of plasma fibrinogen in pregnancy.
Obstet. Gynecol. 47, 299-303.
2. Condie, R. G. & Ogston, D. (1976) Sequential studies on
components of the haemostatic rnechanism in pregnancy
with particular reference to the development of pre-eclamp-
sia. Br. J. Obstet. 83, 938-942.
3. Fletcher, A. R, Alkjaersig, N. K/& Burstein, R. (1979)
The influence of pregnancy upon blood coagulation and
plasma fibrinolytic enzyme function. Am. J. Obstet. Gy-
necol. 734,743-751;
4. Arocha-Pinango, C. L., Linares, J., Cova, A. & Martinez,
P. (1979) Is there a physiological intravascular coagulation
in obstetrical cases? Acta Obstet. Gynecol. Scand. 58,
27^30.
5. Nilsson, I. M. & Kullander, S. (1967) Coagulation and
fibrinolytic studies during pregnancy. Acta Obstet. Gyne-
col. Scand. 46,273-285.
6. Royen, van E. A. (1974) Haemostasis in human pregnancy
and ddivery. Thesis Amsterdam.
7. Gj0nnaess, H. & Fagerhol, M. K. (1975) Studies on co-
agulation and fibrinolysis in pregnancy. Acta Obstet. Gy-
necol. Scand. 54, 363^367.
8. Brakman, P. (1966) The fibrinolytic System in human blood
during pregnancy. Am. J. Obstet. Gynecol. 94, 14—20.
9. Bonnar, J., McNicol, G. P. & Douglas, A. S. (1969) Fi-
brinolytic enzyme system and pregnancy. Br. Med. J. 3,
387-389.
10. Astedt, B. (1972) On fibrinolysis. Part A: In pregnancy,
labour, puerperium and during treatment with sex hor-
mones. Acta Obstet. Gynecol. Scand. 57, 18—26.
11. Condie, R. G. (1976) Components of the haemostatic mech-
anism al birth in pre-eclampsia with particular reference to
fetal growth retardation. Br. J. Obstet. Gynecol. 83, 943-
947.
12. Howie, P. W. (1979) Blood clotting and fibrinolysis in
pregnancy. Postgrad. Med. J. 55, 362—366.
13. Wiman, B., Csemiczky, G., Marsk, L. & Robbe, H. (1984)
The fast inhibitor of tissue plasminogen activator in plasma
during pregnancy. Thromb. Haemostas. 52, 124—126.
14. Kruithof, E. K., Tran-Thang, C., Gudinchet, A., Hauert,
J., Nicoloso, G., Genton, C., Welti, H. & Bachmann, F.
(1987) Fibrinolysis in pregnancy. A study of plasminogen
activator inhibilors. Blood 69, 460—466.
15. Aznar, J., Gilabert, J., Estelles, A. & Espana, F. (1986)
Fibrinolytic activity and Protein C in preeclampsia.
Thromb. Haemostas. 55, 314-317.
16. Estelies, A., Gilabert, J., Espana, F., Aznar, J., Gomez-
Lechon, M. J. (1987) Fibrinolysis in preeclampsia. Fibri-
nolysis l, 209-214.
17. Van Dieyen-Visser, M. R, Salemans T, van Wersch, J. W.
J., Schellekens, L. A. & Brombacher, P. J. (1986) Glyco-
sylated serum proteins and glycosylated haemoglobin in
normal pregnancy. Ann. Clin. Biochem. 23, 661—666.
18. Gilabert, J., Aznar, J., Parrilla, J. J., Reganon, E., Vila, V.
& Estelles, A. (1979) Alterations in the coagulation and
fibrinolysis system in pregnancy labour and puerperium,
with special reference to a possible transitory state of in-
travascular coagulation during labour. Thromb. Haemos-
tas. 40, 387-396.
19. Booth, N. A., MacGregor, I. R.? Hunter, N. R. & Bennett,
B. (1987) Plasminogen activator inhibitor from human en-
dothelial cells. Purification and partial characterization.
Eur. J. Biochem. 165, 595-600.
20. Estelles, A., Gilabert, J., Aznar, J., LoskutofT, D. J. &
Schleef, R. R. (1989) Changes in the plasma levels of type
l and type 2 plasminogen activator inhibitors in normal
pregnancy and in patients with severe preeclampsia. Blood
74, 1332-1338.
21. Riddle, J. M. & Barnhart, M. J. (1965) The eosinophil äs
a source for profibrinolysin in acute inflammation. Blood
25, 776-794.
22. Girolami, A., Lazzaro, A. & Simioni, P. (1988) Thrombotic
manifestations in plasminogen deficicncy and in plasmin-
ogen abnormalitics. Thromb. Haemostas. 60, 528 (Letter),
23. Hach-Wunderle, V., Scharrcr, J. £ Lottcnbcrg, R. (1988)
Congenital deficiency of plaminogen and its rclationship to
vcnous thrombosis. Thromb. Haemostas. 59, 277-280,
Eur. J. Clin. Chcm. Clin, Biochem. / Vol. 29,1991 / No. l
50 van Wersch and Ubachs: Blood coagulation and fibrinolysis in pregnancy
24. Gordon, Y. B., Ratky, S. M., Sola, C. M., Lewis, J., Baker, 25. Ballegeer, V., Mombaerts, R, Declerck, P. J., Spitz^ B., van
L. R. J. & Chard, T. (1975) Circulating levels of fibrin/ Assche, F. A. & Colien, D. (1987) Fibrinölytie response to
fibrinogen degradation fragment E in normal pregnancy, venous occlusion and fibrin fragment D-dimer levels in
and in association with intra-uterine growth retardation normal and complicated pregnancy. Throinb. Haemostas.
and perinatal asphyxia. Br. J. Obstet. Gynaecol. 82, 958- 5$, 1030-1032.
963.
Dr. J. W. J. van Wersch
De Wever Ziekenhuis t
Haematologisch Laboratorium
Postbus 44 46
NL-6401 CX Heerlen
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. l
